Heron Therapeutics (HRTX) Stock Price
Heron Therapeutics Price
Over the last 19 years Heron Therapeutics grew revenue by 19.3% annually, reaching 154.90 M USD. For Heron Therapeutics, the net margin of -13.0% is up versus -252.1% a few years ago.
Heron Therapeutics stock price
Heron Therapeutics business model & stock analysis
Frequently asked questions about Heron Therapeutics
The business model of Heron Therapeutics Inc revolves around developing innovative therapies to address unmet needs in the field of medicine. Heron Therapeutics Inc focuses on creating novel pharmaceutical products, with a particular emphasis on areas such as pain management and supportive care. By leveraging their expertise and scientific advancements, the company aims to improve patient outcomes and enhance their quality of life. Heron Therapeutics Inc actively engages in research and development, clinical trials, and collaborations with healthcare professionals to identify and develop promising therapeutic solutions. This dedication to innovation and patient-centric approaches forms the core of Heron Therapeutics Inc's business model.
Heron Therapeutics Inc is primarily active in the pharmaceutical industry.
The main competitors of Heron Therapeutics Inc in the market include companies like Pfizer Inc., Johnson & Johnson, and AbbVie Inc.
Heron Therapeutics Inc is a pharmaceutical company focused on developing innovative treatments for patients suffering from pain and other unmet medical needs. Established in 1983, Heron Therapeutics has grown steadily over the years, establishing itself as a leader in the field of therapeutics. With a dedication to research and development, the company has successfully brought several products to market, aiming to improve the lives of patients worldwide. Heron Therapeutics Inc's commitment to scientific advancements and patient-centered solutions has garnered recognition and resulted in partnerships with prominent healthcare organizations. With a rich history of innovation, Heron Therapeutics Inc continues to strive towards improving healthcare options and making a positive impact on people's lives.
Heron Therapeutics Inc has achieved several significant milestones. Notably, the company received approval from the U.S. Food and Drug Administration (FDA) for SUSTOL®, their extended-release injection for the prevention of chemotherapy-induced nausea and vomiting. Additionally, Heron Therapeutics developed CINVANTI®, a solution for intravenous use in the same indication. The company has also made advancements in their pain management portfolio, introducing HTX-011, a long-acting local anesthetic, which received FDA approval for postoperative pain management. Heron Therapeutics continues to pursue innovation and deliver effective solutions in the pharmaceutical industry.
Heron Therapeutics Inc is primarily present in the United States.
Heron Therapeutics Inc represents values of innovation, commitment to patient well-being, and scientific excellence. The company's corporate philosophy revolves around developing novel, patient-centered therapeutic solutions to address unmet medical needs. Heron Therapeutics Inc prioritizes the discovery and development of innovative medicines to improve the lives of patients, focusing on areas such as pain management and supportive care. With a strong emphasis on scientific rigor and collaboration, the company constantly strives to deliver cutting-edge healthcare solutions, making a positive impact on patients' lives.
7 analysts currently rate the Heron Therapeutics stock: 0 recommend buying, 4 holding and 3 selling. For 2026, analysts expect Heron Therapeutics to generate revenue of 148.25 M USD and earnings per share of -0.13 USD.
Converted at the current exchange rate, the Heron Therapeutics share trades at 0.35 EUR (0.39 USD).
The Heron Therapeutics share (HRTX) is listed on 7 stock exchanges, including: NASDAQ (HRTX), London (0J4V.L), SIX (Zürich) (AXD2.SW), Frankfurt (AXD2.F), München (AXD2.MU), Düsseldorf (AXD2.DU).
Heron Therapeutics Inc is a biopharmaceutical company specializing in the development and commercialization of products for pain treatment and the relief of nausea and vomiting in cancer patients. The company has been operating in the biotech industry since 1983 and is headquartered in San Diego, California. Heron Therapeutics' business model consists of various areas, with the main ones being research and development, production and supply chain, and marketing and sales. The research and development department of Heron Therapeutics develops innovative therapy approaches for pain treatment and relief of nausea and vomiting. This involves the development of both novel active substances and innovative combinations of active substances to ensure optimal treatment of pain and symptoms. Heron Therapeutics produces its products in-house and maintains a high quality standard. Production is an important part of Heron Therapeutics' business model. The continuous monitoring of processes and compliance with safety standards and quality regulations are of primary importance. In-house production enables rapid market launch and quick adaptation to changing market conditions. Heron Therapeutics has an extensive distribution network and serves customers worldwide. The company's distribution strategy is based on targeted customer segmentation, high sales competence, and optimal market penetration. Heron Therapeutics works closely with partners to establish a comprehensive network and effectively market products in target markets. One important product of Heron Therapeutics is ZYNRELEF, a long-acting local anesthetic for the treatment of postoperative pain. The medication is injected subcutaneously and provides long-lasting pain relief. Another important product is CINVANTI, an intravenously administered medication for the prevention of chemotherapy-induced nausea and vomiting. CINVANTI is based on an established active substance but works faster and more effectively than other products on the market. Overall, Heron Therapeutics' business model is characterized by a clear focus on innovation and customer needs. The company utilizes modern research approaches to develop novel therapies and places great importance on safety and efficacy. Heron Therapeutics has a wide portfolio of products for pain treatment and relief of nausea and vomiting in cancer therapy and has established a worldwide distribution network to provide optimal treatment for patients.
The expected revenue of Heron Therapeutics is 148.25 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Heron Therapeutics is -21.67 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Heron Therapeutics is currently -2.99. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Heron Therapeutics stock.
The price-to-sales ratio (P/S) of Heron Therapeutics is currently 0.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Heron Therapeutics stock.
The Eulerpool Quality Score for Heron Therapeutics is 4/10.
The ISIN of Heron Therapeutics is US4277461020. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Heron Therapeutics is A1XB6K. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Heron Therapeutics is HRTX. The ticker symbol is used to trade Heron Therapeutics shares on the stock exchange.
Heron Therapeutics stock
Heron Therapeutics Peer Group
Heron Therapeutics Ticker
Heron Therapeutics FIGI
All fundamentals and in-depth analysis of Heron Therapeutics
Our stock analysis for Heron Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Heron Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.